KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy, safety, and immunogenicity of UB-851 versus ® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial.

Chien-Hsing Wu, Chih-Chung Shiao, Hsien-Yi Wang, Ya-Chung Tian, Yi-Wen Chiu, Wen-Hung Huang, Shin-Hung Tsai, Hua-Chang Fang, Chin-Chan Lee, Bang-Gee Hsu, Horng-Rong Chang, Chien-Yu Lin, Chee-Hong Chan, Wei-Jie Wang, Kuo-Ching Huang, Szu-Chia Chen, Chia-Liang Wang, Chung-Yu Huang, Der-Cherng Tarng

J Chin Med Assoc 89(1) 35-44

PMID41396155
PMCIDPMC12815523
DOI10.1097/JCMA.0000000000001327
发表日期2025-12-15
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Fig. 1:非 KM 图;Fig. 2:非 KM 图。
摘要

摘要

BACKGROUND: Anemia is a common complication in patients with chronic kidney disease (CKD), for which recombinant human erythropoietin (rhEPO) is the standard treatment. UB-851 is a biosimilar rhEPO developed as an alternative to epoetin alfa (Eprex ® ). This study evaluated the clinical equivalence, safety, and immunogenicity of UB-851 compared with epoetin alfa in patients with anemia due to CKD receiving hemodialysis. METHODS: In this 52-week, multicenter, randomized, parallel-group, phase III trial, patients with anemic CKD undergoing maintenance hemodialysis were assigned to receive either UB-851 or epoetin alfa. Part I (weeks 1-24) included dose titration and hemoglobin (Hb) maintenance. Part II (weeks 25-52) focused on long-term safety and immunogenicity. The primary endpoint was the change in Hb levels from baseline to the efficacy evaluation period (weeks 21-24). The secondary endpoints included epoetin dose, adverse events (AEs), and anti-drug antibody formation. RESULTS: A total of 201 participants were randomized, and the mean change in Hb levels during the efficacy period was within the predefined equivalence margin (±0.6 g/dL) in both the intention-to-treat and per-protocol populations. Differences in weekly epoetin dose changes between the groups also fell within the predefined equivalence range (±45 IU/kg/wk). No significant differences were observed in the laboratory parameters, electrocardiograms, or vital signs. No anti-epoetin antibodies were detected in the UB-851 group. Regarding AEs, the UB-851 appears to be biosimilar to epoetin alfa. CONCLUSION: UB-851 demonstrated clinical equivalence with epoetin alfa in maintaining Hb levels in patients with anemic CKD undergoing hemodialysis. The safety and immunogenicity profiles were comparable, supporting UB-851 as a biosimilar to epoetin alfa.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Fig. 1The study comprised two sequential phases: a 24-wk, double-masked, multicenter, randomized, parallel-group phase to evaluate the efficacy and safety of UB-851 compared with epoetin alfa (Eprex ® ) (randomized in a 2:1 ratio to the UB-851 or epoetin alfa arm), followed by a 28-wk, single-arm, open-label extension phase to assess the long-term safety and immunogenicity of UB-851.
非 KM Figure
Fig. 2A total of 204 patients were randomized (132 patients to the UB-851 arm and 72 patients to the epoetin alfa arm). Of these, 173 patients completed part I and 154 patients completed part II. The discontinuation rates were 15.2% and 9.4% for parts I and II, respectively.
非 KM Figure